Novo Nordisk Abandons Cell Therapy: A Major Shift
Update: 2025-10-10
Description
Novo Nordisk abruptly halts its cell therapy program aimed at curing type 1 diabetes, cutting 250 jobs and ending key partnerships. The pharmaceutical giant is shifting focus, acquiring Akero Therapeutics for $5.2 billion to target liver disease and reducing its workforce by 11% as it pivots away from cell therapy research under its new CEO.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
